Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Multicenter Expanding Phase III Clinical Trial to Evaluate the Safety and Efficacy of Injectable Tyroserleutide to Treat Hepatocellular Carcinoma (HCC) (After HCC Resection)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2020
Price :
$35
*
At a glance
- Drugs Tyroserleutide (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shenzhen Kangzhe Pharmaceutical
- 08 May 2018 New trial record